Promis Neurosciences (PMN) Projected to Release Earnings on Wednesday

Promis Neurosciences (NASDAQ:PMN) is projected to post its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Promis Neurosciences (NASDAQ:PMN) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.10. On average, analysts expect Promis Neurosciences to post ($5.07) EPS for the current fiscal year and ($3.77) EPS for the next fiscal year.

Promis Neurosciences Price Performance

Promis Neurosciences stock traded down $0.20 during midday trading on Wednesday, reaching $3.21. The stock had a trading volume of 107,574 shares, compared to its average volume of 118,805. Promis Neurosciences has a twelve month low of $2.78 and a twelve month high of $27.40. The firm has a market cap of $28.83 million, a price-to-earnings ratio of -0.38 and a beta of -0.19. The firm’s fifty day simple moving average is $10.79 and its two-hundred day simple moving average is $12.81.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PMN shares. Weiss Ratings upgraded Promis Neurosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Chardan Capital set a $20.00 price objective on Promis Neurosciences and gave the stock a “buy” rating in a research note on Monday, July 27th. Roth Capital decreased their price objective on Promis Neurosciences to $15.00 and set a “buy” rating for the company in a research report on Monday. Guggenheim reaffirmed a “buy” rating and set a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. Finally, HC Wainwright reiterated a “buy” rating on shares of Promis Neurosciences in a report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.50.

Insider Activity

In other news, insider Neil Cashman purchased 10,000 shares of Promis Neurosciences stock in a transaction dated Monday, November 2nd. The stock was acquired at an average cost of $3.86 per share, for a total transaction of $38,600.00. Following the acquisition, the insider directly owned 14,532 shares in the company, valued at $56,093.52. This represents a 220.65% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

About Promis Neurosciences

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders.

ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins.